{"id":"https://genegraph.clinicalgenome.org/r/6496d425-6b34-4a38-b635-a7627357d5cbv1.0","type":"EvidenceStrengthAssertion","dc:description":"Bi-allelic variants in *ADAMTS9* are associated with a nephronophthisis-related ciliopathy disease in humans. This is a recent association, first proposed in 2019 (Choi et al., 2019; PMID: 30609407) and currently does not have an official OMIM disease association. Patients in this study shared common phenotypes including proteinuria, end stage renal disease, gross morphological defects in the kidneys and extra-renal features including deafness, and short stature. In contrast, another study (PMID: 34750010) describes bi-allelic variants in *ADAMTS9* being associated with Joubert syndrome-like presentation (complete with the neurological and ocular features) without the renal manifestations.\nIn total, three unrelated individuals harboring bi-allelic variants (missense as well as loss of function) in *ADAMTS9* have been reported in the literature (consisting of the above two studies) presenting with renal and/or extra-renal symptoms. To date, four unique variants have been described associated with disease and were scored in the curation. However, these variants were not all assigned the default points owing to verified consanguinity, population frequency of the variants in databases such as gnomAD, or in silico predictions indicating the variantâ€™s impact on the protein to be likely benign. Taken together, *ADAMTS9* currently has limited genetic case-level data to establish a clear gene-disease relationship.\nFunctional studies performed with transgenic animal models (reviewed but not scored in the curation) have investigated the role of *Adamts9* in development, particularly in the context of the cardiac, cartilage, bone development. However, there are currently no studies that have explored the role of this gene in the renal system. The first study linking *ADAMTS9* to disease (PMID: 30609407) performed functional studies using patient-derived fibroblasts. These studies demonstrated that patient fibroblasts have reduced primary cilia, suggesting a role for ADAMTS9 in cilia formation. Further lines of evidence in mouse epithelial cells indicate a dysfunction in signaling pathways, such as Shh signaling, and impaired spheroid formation. However, these phenotypes have not been directly implicated in the human disease and such findings have also not been demonstrated in a relevant cell line of human origin, although it should be noted that overexpression of human ADAMTS9 was demonstrated to rescue spheroid formation, strongly suggesting a direct involvement of the protein in this process. In addition, a study (PMID: 30814516) has explored the role of Adamts9 in ciliary trafficking using mice models, but the genetic background of this model is not consistent with the human disease context. Therefore, in keeping with the gene curation SOP guidelines, this evidence has been either only reviewed or scored with reduced points. Default points were given to the morpholino-mediated knockdown of *Adamts9* in zebrafish that caused curved body axis, hydrocephalus, and pronephric cysts (PMID: 30609407).\nIn summary, due to the limited genetic evidence as well as the absence of renal-specific experimental evidence, the causal relationship between the bi-allelic variants in *ADAMTS9* and its associated disease ciliopathy cannot be unequivocally determined at this time. Therefore, this gene-disease relationship, based on our scoring of currently available information has been determined as limited. This classification was approved by the ClinGen Kidney Cystic and Ciliopathy Disorders GCEP on the meeting date 05/11/22 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6496d425-6b34-4a38-b635-a7627357d5cb","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10066","date":"2022-05-11T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10066","date":"2022-09-15T20:08:58.869Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e49db39-26d9-4208-a222-ddbdee33a919_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d8235d22-6b04-42d4-990e-06824a984ea8","type":"EvidenceLine","dc:description":"This variant, based on table 1 in paper and dbSNP (rs771577187) is common in general population with 36 hets in the Japanese, and classified as VUS, per ACMG guidelines. Since downgrading it to the next possible score will result in it being 0, this variant is curated but not scored. ","calculatedScore":0.1,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d8235d22-6b04-42d4-990e-06824a984ea8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34750010","allele":{"id":"https://genegraph.clinicalgenome.org/r/a00f2236-dd09-4f2b-ad18-4a092f269301","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182920.2(ADAMTS9):c.1940G>A (p.Arg647Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2481358"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/65788906-9001-4499-a211-674a63fd97fa","type":"EvidenceLine","dc:description":"This variant, based on table 1 in paper and dbSNP (rs768501919) is common in general population with 22 hets in the Japanese, and classified as VUS, per ACMG guidelines. Since downgrading it to the next possible score will result in it being 0, this variant is curated but not scored. ","calculatedScore":0.1,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/65788906-9001-4499-a211-674a63fd97fa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34750010","allele":{"id":"https://genegraph.clinicalgenome.org/r/de24568b-fe2d-49c8-9ce9-5e9014fe6525","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182920.2(ADAMTS9):c.3607C>T (p.Arg1203Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2480757"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4e49db39-26d9-4208-a222-ddbdee33a919","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34750010","rdfs:label":"Family1-P","allele":[{"id":"https://genegraph.clinicalgenome.org/r/de24568b-fe2d-49c8-9ce9-5e9014fe6525"},{"id":"https://genegraph.clinicalgenome.org/r/a00f2236-dd09-4f2b-ad18-4a092f269301"}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Motor developmental delay, hypotonia, mild bifid tongue, bilateral hyperopia and OMA, mild hypoplasia of the cerebellar vermis, indicates molar tooth sign (MTS), though incomplete.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d8235d22-6b04-42d4-990e-06824a984ea8_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/65788906-9001-4499-a211-674a63fd97fa_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/3a3df50e-4a45-414e-b35f-942a0e845396_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4576487d-3808-4ec5-8459-40793dcd01a4","type":"EvidenceLine","dc:description":"Scored 1 instead of default score of 2 due to consanguinity. ","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4576487d-3808-4ec5-8459-40793dcd01a4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fig2D demonstrates that while WT ADAMTS9 localizes at basal body of cilia, this patient variant does not. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4576487d-3808-4ec5-8459-40793dcd01a4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","allele":{"id":"https://genegraph.clinicalgenome.org/r/aad104b7-9345-4389-a1d4-8266099b9250","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182920.2(ADAMTS9):c.4575_4576del (p.Gln1525fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1344639"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3a3df50e-4a45-414e-b35f-942a0e845396","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"F1279-21-P","allele":{"id":"https://genegraph.clinicalgenome.org/r/aad104b7-9345-4389-a1d4-8266099b9250"},"detectionMethod":"Homozygosity mapping and WES in >100 consanguineous individuals or siblings of index individuals who were also affected with NPHP-RC.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"End-stage renal disease (ESRD), proteinuria, medullary cysts, corpus callosum hypoplasia and aplasia of the vermis,  deafness, atrial septal defects, coloboma, and short stature.","previousTesting":false,"secondTestingMethod":"Exome sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4576487d-3808-4ec5-8459-40793dcd01a4_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c2f0f6cf-7702-43f7-a90c-3e6918531103_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57674e13-3f3b-4020-bda6-d2544e806e8f","type":"EvidenceLine","dc:description":"Downgrading from 0.5 to 0.25 due to family consanguinity. Further downgrading it from 0.25 to 0.1 since to in silico pathogenicity predictors are leaning benign on this variant- Find below the tool (score, verdict) REVEL (0.164, benign), MetaLR (0.2034, tolerated), METASVM(-0.7815, tolerated), MetaRNN (0.102, tolerated), CADD (22.9), BayesDel (tolerated), EIGEN(0.3739, pathogenic), EIGEN PC (Pathogenic, 0.4467), FATHMM (0.08, 0.26,0.3, tolerated), FATHMM-MKL (0.8856, damaging), FATHMM-XF (0.7652, damaging), SIFT (0.154, 0.384, tolerated), SIFT-4G(0.206,0.228, tolerated) MutationTaster(0.99, disease-causing), PROVEAN (-0.9, -0.51, Neutral), MutationAssessor (1.65, low). \nFurther, according to dbSNP, this variant is fairly common in heterozygous state in the population with one homozygote in gnomAD (rs192420947 ).","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57674e13-3f3b-4020-bda6-d2544e806e8f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fig.2D describes that this variant does not localize to cilia basal body while WT ADAMTS9 does.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/57674e13-3f3b-4020-bda6-d2544e806e8f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","allele":{"id":"https://genegraph.clinicalgenome.org/r/7764a78a-8fa6-4998-a5b4-f22b3893c72d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182920.2(ADAMTS9):c.194C>G (p.Thr65Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1344640"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/c2f0f6cf-7702-43f7-a90c-3e6918531103","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"A5048-21-P","allele":{"id":"https://genegraph.clinicalgenome.org/r/7764a78a-8fa6-4998-a5b4-f22b3893c72d"},"ethnicity":{"id":"cg:UnknownEthnicity"},"phenotypeFreeText":"NPHP, nonselective proteinuria, ESRD since infancy, Microcystic dilatation of tubules, immature glomeruli, sensorineural deafness, hepatosplenomegaly, short stature, anemia, thrombocytopenia, osteopenia, rickets","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/57674e13-3f3b-4020-bda6-d2544e806e8f_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f01feb70-911a-40ac-ba58-61eaf8db8ee4_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"A5048-21","family":{"id":"https://genegraph.clinicalgenome.org/r/f01feb70-911a-40ac-ba58-61eaf8db8ee4","type":"Family","rdfs:label":"A5048-21","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/c2f0f6cf-7702-43f7-a90c-3e6918531103"}},"phenotypeFreeText":"NPHP, nonselective proteinuria, ESRD since infancy, Microcystic dilatation of tubules, immature glomeruli, sensorineural deafness, hepatosplenomegaly, short stature, anemia, thrombocytopenia, osteopenia, rickets","phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/c2f0f6cf-7702-43f7-a90c-3e6918531103"}},{"id":"https://genegraph.clinicalgenome.org/r/69711a85-2deb-4416-a5ee-4c30c6f742bc_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34750010","rdfs:label":"Family1","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/69711a85-2deb-4416-a5ee-4c30c6f742bc","type":"Family","rdfs:label":"Family1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/4e49db39-26d9-4208-a222-ddbdee33a919"}},"phenotypeFreeText":"Motor developmental delay, hypotonia, mild bifid tongue, bilateral hyperopia and OMA, mild hypoplasia of the cerebellar vermis, indicates molar tooth sign (MTS), though incomplete.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/4e49db39-26d9-4208-a222-ddbdee33a919"}},{"id":"https://genegraph.clinicalgenome.org/r/e2f2fa40-02c3-4938-a9ae-81e884ac5a83_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"F1279-21","family":{"id":"https://genegraph.clinicalgenome.org/r/e2f2fa40-02c3-4938-a9ae-81e884ac5a83","type":"Family","rdfs:label":"F1279-21","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/3a3df50e-4a45-414e-b35f-942a0e845396"}},"phenotypeFreeText":"End-stage renal disease (ESRD), proteinuria, corpus callosum hypoplasia and aplasia of the vermis,  deafness, atrial septal defects, coloboma, and short stature.","phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/3a3df50e-4a45-414e-b35f-942a0e845396"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":2.2},{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ff7b4a2-975f-490d-b67d-fb2a6bc1bb43","type":"EvidenceLine","dc:description":"Since this is an extra-renal feature, it is curated but not scored.","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ac9a9afa-cae1-443f-8f49-07e0f4630bc7","type":"Finding","dc:description":"Patients with biallelic ADAMTS9 variants exhibited septal defects like the mice with adamts9 haploinsufficiency. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20096780","rdfs:label":"adamts9 haploinsufficiency","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e2e24061-5ff1-4a4d-878a-e1e5a8e20750","type":"EvidenceLine","dc:description":"Since this model has extra renal features, this evidence is curated but not reviewed.","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c52cd87e-d4d1-4db9-8318-389a0f4c1d36","type":"Finding","dc:description":"Not only do the fish recapitulate the eye defects in patients, it also phenocopies the likely variable expressivity and penetrance of the eye phenotypes as not all patients have eye features. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290818","rdfs:label":"ENU Screen-Fig8","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ed364de0-929b-4735-b99c-b191fb5e05c9","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a35eab38-7264-4128-9941-ae4068026d6e","type":"Finding","dc:description":"Renal cysts were recapitulated in the model system. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"Zebrafish model-Fig.5","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f730d70d-d4c5-4509-9e95-97c4abd9e8cf","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c44dbb10-f6e0-4ccf-b68d-48948a8d1db9","type":"Finding","dc:description":"Shorter primary cilia are observed in various ciliopathies including Joubert Syndrome, BBS, Lowe Syndrome. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"CellCuture-Fig3B","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ccc2a7f1-a1d0-4b8b-8c23-09f488be31b0","type":"EvidenceLine","dc:description":"Only reviewing this under experimental section since this was already scored under genetic evidence with functional testing","calculatedScore":1,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e9ef73b-8d9b-4c88-af41-0c9a20249aa3","type":"Finding","dc:description":"Absence of this protein at basal body may affect ciliary function which could be linked to nephronophthisis in patients. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"BasalBody localization","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/06529a87-1a4b-4c8d-87f5-a7c7b56e08be","type":"EvidenceLine","dc:description":"Downgrading this to 0.5 since the cell lines used were mouse Inner Medullary Collecting Duct-3 lines and not human lines and it is not known if it is the right region of the kidney that is pathologically affected by alterations in ADAMTS9. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d79e54d-e865-451c-b894-ddb364c8b350","type":"Finding","dc:description":"WT ADAMTS9 overexpressed in spheroids lacking endogenous ADAMTS9 reduced the number of defective spheroids that had poor apicobasal polarity. Expressing patient variants in spheroids lacking endogenous ADAMTS9 could not rescue this phenotype. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"Spheroid formation","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a7e1d16-e5ee-4892-8836-43ba2a3816bf","type":"EvidenceLine","dc:description":"Per page 40 of the SOP, \"Functional Alteration: Evidence showing that cultured cells, in which the function of the gene has been disrupted, have a phenotype that is consistent with the human disease process.\" We currently do not know if Shh signaling alteration is responsible (even partly) for the human phenotypes. hence downgrading this. The evidence is still being scored since a similar pattern of Shh alteration has been observed in ciliopathies linked to other genes such as INPP5E, but as the evidence stands, its limited and not very strongly suggestive of a mechanism. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0d88c938-8f24-4e5c-aef3-6d4879000faf","type":"FunctionalAlteration","dc:description":"IN cells expressing ADAMTS9, Smo was observed to be translocated to the primary cilia upon stimulation using SAG (a Smo agonist). In the absence of ADAMTS9, Smo was not translocated to the cilia and SMO, GLI1 mRNA was also reduced. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30609407","rdfs:label":"Shh signaling-Fig3"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.75}],"evidenceStrength":"Limited","sequence":4997,"specifiedBy":"GeneValidityCriteria8","strengthScore":5.95,"subject":{"id":"https://genegraph.clinicalgenome.org/r/veBSxXJ9i3Q","type":"GeneValidityProposition","disease":"obo:MONDO_0005308","gene":"hgnc:13202","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a31b47e0-c9a5-4bdd-99d7-2d7f0d2a3bc8-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}